Results 131 to 140 of about 125,568 (336)
Chloroquine for the 2019 novel coronavirus SARS-CoV-2
P. Colson, J. Rolain, D. Raoult
semanticscholar +1 more source
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane +33 more
wiley +1 more source
Objective We evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011–2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman +6 more
wiley +1 more source
Treatment of Melanoma Cells with Chloroquine and Everolimus Activates the Apoptosis Process and Alters Lipid Redistribution [PDF]
Dorota Ciołczyk-Wierzbicka +4 more
openalex +1 more source
Background Using hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.
Shivani Garg +42 more
wiley +1 more source
In vitro sensitivity pattern of chloroquine and artemisinin in Plasmodium falciparum
Supriya Sharma +6 more
openalex +1 more source
Effective treatment with a tetrandrine/chloroquine combination for chloroquine-resistant falciparum malaria in Aotus monkeys [PDF]
Zuguang Ye +2 more
openalex +1 more source

